The CMR Green Technologies IPO subscription opened on June 3, 2026, and will close on…

Hannah Joseph Hospital IPO Subscription Closes With Moderate Demand
The initial public offering (IPO) of Hannah Joseph Hospital is drawing to a close today, Wednesday, January 28, 2026, marking the end of its three-day subscription period that began on Thursday, January 22, 2026. The IPO has been subscribed ~1.32 times, a sign of moderate investor interest as bidding concludes.

Subscription and Investor Response
• The IPO received bids for 5.7 million shares against 4.29 million shares on offer as of late morning data.
• Non-Institutional Investors (NIIs) led the demand with a subscription of 1.60 times, while retail individual investors contributed a 1.44 times subscription.
• The portion reserved for Qualified Institutional Buyers (QIBs) saw lower interest, being subscribed to 88%.

IPO Pricing and Investment Details
• The public issue is entirely a fresh issue of 6 million equity shares aggregating to around ₹42 crore. There is no offer-for-sale component.
• The IPO price band was fixed at ₹67 to ₹70 per share, with a lot size of 2,000 shares.
• At the upper price band, a retail investor would need roughly ₹2,80,000 to apply for two lots (4,000 shares).

Grey Market and Expected Allotment Timeline
• In the grey market, unlisted shares of Hannah Joseph Hospital were trading flat at ₹70, which is the upper end of the price band, suggesting neutral sentiment on listing gains.
• As the IPO subscription ends today, the **basis of allotment is likely to be finalised on Thursday, January 29, 2026.
• Shares are expected to be credited to investors’ demat accounts on **Friday, January 30, 2026, with a **tentative listing on the BSE SME platform on **Sunday, February 1, 2026.
Company and IPO Use of Proceeds
• Hannah Joseph Hospital operates a 150-bed multi-speciality hospital in Madurai, offering services across neurology, cardiology, psychiatry and trauma care.
• According to disclosures, net proceeds from the IPO are planned to be used for establishing a Radiation Oncology Centre and for general corporate purposes.